Inspiremd Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Inspiremd Inc 's ROA in the second quarter of 2026?
Inspiremd Inc recorded a cumulative net loss of $-52 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -84.31%.

However, within the Healthcare sector 701 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4204, from total ROA ranking in the first quarter of 2026 at 4908.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	33.89 %	46.03 %	56.15 %	59.06 %	-38.71 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-52	-51	-49	-46	-41
Return On Assets (TTM)	-84.31 %	-86.35 %	-88.75 %	-94.8 %	-99.84 %
NSPR's Total Ranking	# 4204	# 4908	# 4362	# 4444	# 4383
Total Assets (TTM) in million	45	56	69	78	33
Seq. Total Assets Change	-20.95 %	-18.63 %	-11.56 %	135.35 %	-13.78 %
Seq. Net Income Change	-	-	-	-	-

NSPR's 5 Years Annual ROA >> Back to NSPR Management Effectiveness >> Compare NSPR ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 165
Sector	# 702
Overall	# 4157

Return On Assets Statistics
High	Average	Low
-33.65 %	-106.52 %	-215.04 %
(Dec 31 2021)		(Sep 30 2014)

News about Inspiremd Inc Return on Assets ROA

InspireMD Advances with PMA Submission for CGuard Prime Carotid Stent System Following Successful Clinical Trial Outc...

InspireMD Moves Forward with FDA Premarket Approval Application for CGuard Prime Carotid Stent: A Leap in Vascular Technology In a significant advancement for vascular intervention, InspireMD has officially submitted a Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its innovative CGuard Prime Carotid Stent System. This pivotal move is grounded in the overwhelmingly positive results from the C-GUARDIANS clinical study, which showcased compelling efficacy and safety data that were initially unveiled at the prestigious LINC conference in May 2024.The CGuard Prime Carotid Stent System represents a technological evolution in minimizing the risks associated with carotid artery disease a condition that can lead to debilitating strokes. This stent system is distinct for its proprietary design, which integrates a unique mesh covering that aims to prevent plaque build-up while maintaining optimal blood flow. Such innovation is timely, as cardiovascular diseases remain a leading cause of morbidity and mortality worldwide.

InspireMD Appoints Pete Ligotti as EVP and GM of North America Amidst Financial Struggles: A New Hope for the Company's Future

InspireMD, a leading medical technology company, has recently announced the appointment of Pete Ligotti as their new Executive Vice President and General Manager of North America. Ligotti, a highly experienced medical technology executive, brings over 30 years of general management and commercial leadership expertise to the InspireMD team. This strategic move reflects the company s commitment to expanding its presence in the North American market and driving growth in the healthcare sector.
Despite the promising addition of Ligotti to their leadership team, InspireMD has recorded a cumulative net loss of $-19 million during the 12 months ending in the second quarter of 2023. This has resulted in a negative return on assets (ROA) of -57.48%. It is essential to note that the negative ROA indicates the company s inability to generate profits from its assets during this period.

Financial Statements
Inspiremd Inc 's Assets	$ 45 million	NSPR's Balance sheet
Inspiremd Inc 's Income	$ -14 million	Quarterly NSPR's Income Statement
NSPR's Income by Division		See NSPR's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	49.94 %	-3.73 %	99.88 %	-40.21 %	133.96 %
Total Assets in million	67	44	46	23	39
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-49	-32	-20	-18	-15
Annual Return On Assets	-73.2 %	-72.01 %	-43.14 %	-80.05 %	-38.62 %

NSPR's 5 Years Annual ROA >> Back to NSPR Management Effectiveness >> Compare NSPR ROA to its Competitors

More Return On Assets Ratios
NSPR's' Return on Assets at Yahoo Finance
Medical Equipment & Supplies Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
NSPR's Roa Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for NSPR's Competitors
Subscribers only: Roa for Inspiremd Inc 's Suppliers
Subscribers only: Return On Assets for NSPR's Customers

You may also want to know
NSPR's Roi	NSPR's Inventory Turnover Ratio	NSPR's Growth Rates	NSPR's Dividend Comparisons
	NSPR's Profitability Ratios	NSPR's Asset Turnover Ratio	NSPR's Dividend Growth
NSPR's Roe	NSPR's Valuation Ratios	NSPR's Financial Strength Ratios	NSPR's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-08-16T05:15:05+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.